Tobias Schlosser, Marco Krasselt, Martin Hecker, Babett Holler, Albrecht Hoffmeister
{"title":"Post-COVID-19 Condition has High Prevalence in Patients with Immune-mediated Inflammatory Diseases and Negatively Impacts Quality of Life.","authors":"Tobias Schlosser, Marco Krasselt, Martin Hecker, Babett Holler, Albrecht Hoffmeister","doi":"10.4103/jgid.jgid_142_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pandemic situation by severe acute respiratory syndrome coronavirus 2 and the associated disease (coronavirus disease 2019 [COVID-19]) presents broad challenges. Post-COVID-19 condition represents a continuum of persistent symptoms following the acute course. The World Health Organization (WHO) proposes a definition with at least one symptom persisting for 3 months postonset. Negative affection toward quality of life (QoL) is frequently reported. Patients with immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease (IBD) and rheumatic diseases (RDs) are of scientific interest as immunologic factors and immunosuppressive therapy might influence QoL in post-COVID-19 conditions.</p><p><strong>Methods: </strong>Adult IMID patients (≥18 years) were offered participation in this study at our university outpatient center. Data collection was questionnaire-based and recorded individual COVID-19 history and persisting symptoms. QoL has been assessed by several standardized and validated patient-reported outcome measures (Short IBD Questionnaire and Patient Health Questionnaire 4, 5Q-5D-5L).</p><p><strong>Results: </strong>A total of 156 patients were included (117 [75%] with IBD, 39 [25%] with RDs). Eighty-one patients (51%) reported a positive COVID-19 history, mostly with mild courses. Only two (2%) required hospitalization, one requiring intensive care. Seven (9%) reported no symptoms, while 20 (25%) met the WHO criterion for post-COVID-19 condition; 19 (23%) were still suffering from post-COVID-19 at the time of data acquisition. Mean/median global QoL scores (scale from 0 [=lowest] to 100 [=highest]) were 71.5/75 in patients without post-COVID-19, compared to 61.9/60 in those with the condition. A one-sided <i>t</i>-test showed a significant association between post-COVID-19 and lower QoL (<i>P</i> = 0.03).</p><p><strong>Conclusions: </strong>A relevant fraction of IMID patients suffered from post-COVID-19 condition. This condition negatively impacted the individual QoL.</p>","PeriodicalId":51581,"journal":{"name":"Journal of Global Infectious Diseases","volume":"18 3","pages":"122-133"},"PeriodicalIF":1.3000,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679952/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Global Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jgid.jgid_142_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pandemic situation by severe acute respiratory syndrome coronavirus 2 and the associated disease (coronavirus disease 2019 [COVID-19]) presents broad challenges. Post-COVID-19 condition represents a continuum of persistent symptoms following the acute course. The World Health Organization (WHO) proposes a definition with at least one symptom persisting for 3 months postonset. Negative affection toward quality of life (QoL) is frequently reported. Patients with immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease (IBD) and rheumatic diseases (RDs) are of scientific interest as immunologic factors and immunosuppressive therapy might influence QoL in post-COVID-19 conditions.
Methods: Adult IMID patients (≥18 years) were offered participation in this study at our university outpatient center. Data collection was questionnaire-based and recorded individual COVID-19 history and persisting symptoms. QoL has been assessed by several standardized and validated patient-reported outcome measures (Short IBD Questionnaire and Patient Health Questionnaire 4, 5Q-5D-5L).
Results: A total of 156 patients were included (117 [75%] with IBD, 39 [25%] with RDs). Eighty-one patients (51%) reported a positive COVID-19 history, mostly with mild courses. Only two (2%) required hospitalization, one requiring intensive care. Seven (9%) reported no symptoms, while 20 (25%) met the WHO criterion for post-COVID-19 condition; 19 (23%) were still suffering from post-COVID-19 at the time of data acquisition. Mean/median global QoL scores (scale from 0 [=lowest] to 100 [=highest]) were 71.5/75 in patients without post-COVID-19, compared to 61.9/60 in those with the condition. A one-sided t-test showed a significant association between post-COVID-19 and lower QoL (P = 0.03).
Conclusions: A relevant fraction of IMID patients suffered from post-COVID-19 condition. This condition negatively impacted the individual QoL.
期刊介绍：
JGID encourages research, education and dissemination of knowledge in the field of Infectious Diseases across the world thus promoting translational research by striking a synergy between basic science, clinical medicine and public health. The Journal intends to bring together scientists and academicians in Infectious Diseases to promote translational synergy between Laboratory Science, Clinical Medicine and Public Health. The Journal invites Original Articles, Clinical Investigations, Epidemiological Analysis, Data Protocols, Case Reports, Clinical Photographs, review articles and special commentaries. Students, Residents, Academicians, Public Health experts and scientists are all encouraged to be a part of this initiative by contributing, reviewing and promoting scientific works and science.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
